Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 20/20 | 0.82 |
| ▸ | RICTOR | Q6R327 | 14/20 | 0.82 |
| ▸ | RPTOR | Q8N122 | 14/20 | 0.82 |
| ▸ | MAPKAP1 | Q9BPZ7 | 14/20 | 0.82 |
| ▸ | MLST8 | Q9BVC4 | 14/20 | 0.82 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.62 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.52 |
| ▸ | ABL1 | P00519 | 2/20 | 0.52 |
| ▸ | PRKDC | P78527 | 2/20 | 0.50 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30382307 | 1.00 | MTOR (0.82) | MTORRICTORRPTORMAPKAP1MLST8 | |
| SCHEMBL22494321 | 0.91 | MTOR (0.83) | MTORRICTORRPTORMAPKAP1MLST8 | |
| SCHEMBL22494282 | 0.90 | MTOR (1.00) | MTORRICTORRPTORMAPKAP1MLST8 | |
| SCHEMBL22494407 | 0.86 | MTOR (0.82) | MTORRICTORRPTORMAPKAP1MLST8 | |
| SCHEMBL22494290 | 0.86 | MTOR (0.80) | MTORRICTORRPTORMAPKAP1MLST8 | |
| SCHEMBL22494410 | 0.86 | MTOR (0.80) | MTORRICTORRPTORMAPKAP1MLST8 | |
| SCHEMBL22494275 | 0.85 | MTOR (0.79) | MTORRICTORRPTORMAPKAP1MLST8 | |
| SCHEMBL24914784 | 0.85 | MTOR (0.79) | MTORRICTORRPTORMAPKAP1MLST8 | |
| SCHEMBL22494343 | 0.82 | MTOR (0.75) | MTORRICTORRPTORMAPKAP1MLST8 | |
| SCHEMBL26440090 | 0.81 | MTOR (0.73) | MTORRICTORRPTORMAPKAP1MLST8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731973-B2 | Substituted pyrazolo[3,4-d]pyrimidines as mTOR inhibitors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2023-08-22 | — | — | US | claimed |
| EP-3727389-B1 | COMPOUNDS AS MTOR INHIBITORS | GALDERMA RES & DEV (FR) | 2023-05-03 | — | — | EP | claimed |
| US-11731973-B2 | Substituted pyrazolo[3,4-d]pyrimidines as mTOR inhibitors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2023-08-22 | — | — | US | disclosed |
| US-11731973-B2 | Substituted pyrazolo[3,4-d]pyrimidines as mTOR inhibitors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2023-08-22 | — | — | US | disclosed |
| US-11731973-B2 | Substituted pyrazolo[3,4-d]pyrimidines as mTOR inhibitors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2023-08-22 | — | — | US | disclosed |
| EP-3727389-B1 | COMPOUNDS AS MTOR INHIBITORS | GALDERMA RES & DEV (FR) | 2023-05-03 | — | — | EP | disclosed |
| EP-3727389-B1 | COMPOUNDS AS MTOR INHIBITORS | GALDERMA RES & DEV (FR) | 2023-05-03 | — | — | EP | disclosed |
| US-20200317679-A1 | NOVEL MTOR INHIBITOR COMPOUNDS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-10-08 | — | — | US | disclosed |
| US-20200317679-A1 | NOVEL MTOR INHIBITOR COMPOUNDS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317679-A1 | NOVEL MTOR INHIBITOR COMPOUNDS | MTOR, RICTOR, RPTOR | MTOR 1/4885RICTOR 2/4885RPTOR 3/4885 |
| US-11731973-B2 | Substituted pyrazolo[3,4-d]pyrimidines as mTOR inhibitors | MTOR, RICTOR, RPTOR | MTOR 1/4885RICTOR 2/4885RPTOR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.